These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33972144)

  • 21. Intraoperative Touch Imprint Cytology in Targeted Axillary Dissection After Neoadjuvant Chemotherapy for Breast Cancer Patients with Initial Axillary Metastasis.
    Wu S; Wang Y; Zhang N; Li J; Xu X; Shen J; Liu G
    Ann Surg Oncol; 2018 Oct; 25(11):3150-3157. PubMed ID: 30083833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma.
    Adachi Y; Sawaki M; Hattori M; Yoshimura A; Gondo N; Kotani H; Iwase M; Kataoka A; Onishi S; Sugino K; Terada M; Horisawa N; Mori M; Oze I; Iwata H
    Breast Cancer; 2018 Sep; 25(5):560-565. PubMed ID: 29536376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery.
    Kozak MM; Horst KC; Gutkin PM; Jacobson CE; Walck E; von Eyben R; Dirbas FM
    Clin Breast Cancer; 2020 Oct; 20(5):431-438. PubMed ID: 32522481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissection.
    Espinosa-Bravo M; Navarro-Cecilia J; Ramos Boyero M; Diaz-Botero S; Dueñas Rodríguez B; Luque López C; Ramos Grande T; Ruano Perez R; Peg V; Rubio IT
    Breast; 2017 Feb; 31():40-45. PubMed ID: 27810698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axillary treatment of patients with breast cancer and micrometastatic disease in the sentinel lymph node Our experience.
    Morlino A; La Torre G; Patitucci G; Cammarota A
    Ann Ital Chir; 2017; 88():360-364. PubMed ID: 29051403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of a breast cancer nomogram for predicting nonsentinel node metastases after minimal sentinel node involvement: validation of the Helsinki breast nomogram.
    Ouldamer L; Arbion F; Balagny A; Fourquet F; Marret H; Body G
    Breast; 2013 Oct; 22(5):787-92. PubMed ID: 23473772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Partial axillary lymph node dissection inferior to the intercostobrachial nerves complements sentinel node biopsy in patients with clinically node-negative breast cancer.
    Li J; Jia S; Zhang W; Qiu F; Zhang Y; Gu X; Xue J
    BMC Surg; 2015 Jun; 15():79. PubMed ID: 26123412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staging breast cancer by sentinel lymph node biopsy: Do patients with a single negative sentinel node (N=1) experience worse outcomes than those with multiple negative sentinel nodes (N>1)?
    Wilkerson A; Averbook B; Joseph N; Sharpe S; Li B
    Surg Oncol; 2018 Sep; 27(3):327-332. PubMed ID: 30217285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
    Moo TA; Edelweiss M; Hajiyeva S; Stempel M; Raiss M; Zabor EC; Barrio A; Morrow M
    Ann Surg Oncol; 2018 Jun; 25(6):1488-1494. PubMed ID: 29572705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.
    Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H
    Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
    Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK
    Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients.
    Heuts EM; van der Ent FW; Hulsewé KW; Heeren PA; Hoofwijk AG
    Acta Chir Belg; 2007 Jun; 107(3):279-83. PubMed ID: 17685253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined procedure of marking axillary positive node with iodine-125 seed and sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
    Custodio Rebollo Aguirre A; Sánchez Sánchez R; González Jiménez AD; Culiañez Casas M; Mendoza Arnau I; Rashki M; Rudolphi Solero T; Martínez Meca S
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):75-83. PubMed ID: 31759957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
    Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
    Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sentinel node biopsy and neoadjuvant chemotherapy in the treatment of breast cancer.
    Gatek J; Vrana D; Hnatek L; Bakala J; Dudesek B; Duben J; Musil T
    J BUON; 2012; 17(2):265-70. PubMed ID: 22740204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection.
    Cyr A; Gao F; Gillanders WE; Aft RL; Eberlein TJ; Margenthaler JA
    Ann Surg Oncol; 2012 Oct; 19(10):3185-91. PubMed ID: 22890591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.